Cell Genesys Inc.

cell genesys inc. - All News and Analysis

• Cell Genesys, Inc. Q3 2008 Earnings Call Transcript

  Seeking Alpha - 2008-11-18

  Question-and-Answer SessionOperator Right, thank you. Operator instructions And our first question comes from Pamela Bassett from Cantor Fitzgerald. Please go ahead. Pamela Bassett – Cantor Fitzgerald Hi, thanks for taking my call. Sharon Tetlow Hi, Pamela. Pamela Bassett – Cantor Fitzgerald Hi. I’m wondering –...

  Tags: Asset, Acquisition, Call Transcript, Earnings, Cell Genesys Inc., Mergers & Acquisitions, Asset Management, Corporate Law, Investment, Finance, Operational Planning, Business Operations, Seeking Alpha

• Cell Genesys, Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-09-01

  Question-and-Answer Session Operator Operator instructions. Our first question then today is from the line of Joe Pantginis with Canaccord Adams. Please go ahead. Joseph Pantginis – Canaccord Adams Hi, guys, good afternoon. Stephen Sherwin Hi. Joseph Pantginis – Canaccord Adams Steve, a...

  Tags: Cell Genesys Inc.

• Five Biopharma Companies Drop on Negative Drug News

  Seeking Alpha - 2008-08-28

  Mike Huckman submits: Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals AMLN and Cell Genesys CEGE, much lower. After the closing bell Tuesday, Bristol-Myers Squibb BMY and Pfizer PFE announced a bloodclot drug...

  Tags: Healthcare, Biotech, Amylin Pharmaceuticals Inc., Bristol-Myers Squibb Co., Cell Genesys Inc., Eli Lilly & Co., Pfizer Inc.

• Cell Genesys, Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-18

  Question-and-Answer Session Operator Operator instructions We'll go first to the line of Joe Pantginis from Canaccord Adams. Please go ahead. Joe Patginis – Canaccord Adams Hi guys, good afternoon. Just two questions, if you will. The first one is on Takeda and the second is on...

  Tags: Cell Genesys Inc.

• Turning Pennies into dollars: (Nasdaq: CEGE), (NASDAQ: ACUS), (OTCBB: XDSL).

  - 2008-04-02

  M2 PRESSWIRE-2 April 2008-RealPennies.com: Turning Pennies into dollars: (Nasdaq: CEGE), (NASDAQ: ACUS), (OTCBB: XDSL).C1994-2008 M2 COMMUNICATIONS LTD RDATE:02042008 Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559 For more info: http://cege.realpennies.com ...

  Tags: Cell, Cell Genesys Inc., commercialization, Components, HARDWARE, mPhase Technologies Inc., Nasdaq Stock Market Inc., Processors, Semiconductors, Takeda

• Cell Genesys, Inc. Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-02-27

  Question-and-Answer Session Operator Operator Instructions Our first question comes from the line of Joe Pantginis - Canaccord Adams. Joe Pantginis - Canaccord Adams Steve, the added immunological data at ASCO GU were obviously very promising. You identified some control antigens that you talked about, and...

  Tags: Cell Genesys Inc.

• Growth Watch.

  - 2007-07-10

  M2 PRESSWIRE-10 July 2007-Bullishalerts.com: Growth WatchC1994-2007 M2 COMMUNICATIONS LTD RDATE:10072007 Philadelphia, PA - Bullish Alerts is currently monitoring the following Stocks: Ocean Bio-Chem, Inc. Nasdaq OBCI, Applied Micro Circuits Corporation (Nasdaq: AMCC), Cell Genesys, Inc. (Nasdaq: CEGE) and Generex Biotechnology...

  Tags: Cell Genesys Inc., Company, Components, FINANCE, Generex Biotechnology Corp., HARDWARE, Investment, Nasdaq Stock Market Inc., Processors, SALES, Semiconductors

• Cell Genesys to Present at the Acumen Biofin Rodman & Renshaw Global Healthcare Conference.

  - 2007-05-07

  M2 PRESSWIRE-7 May 2007-Morning Movers: Cell Genesys to Present at the Acumen Biofin Rodman & Renshaw Global Healthcare ConferenceC1994-2007 M2 COMMUNICATIONS LTD RDATE:07052007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a...

  Tags: Cell, Cell Genesys Inc., Components, FINANCE, HARDWARE, investor, Nasdaq Stock Market Inc., Processors, security, Semiconductors

• More Breaking Headlines from VIASPACE Inc. (OTCBB: VSPC).

  - 2007-04-12

  M2 PRESSWIRE-12 April 2007-SmallCapStockAlert.com: More Breaking Headlines from VIASPACE Inc. (OTCBB: VSPC)C1994-2007 M2 COMMUNICATIONS LTD RDATE:12042007 Stocks to Watch: VIASPACE Inc. (OTCBB: VSPC), Cell Genesys, Inc. (Nasdaq:CEGE), The Stallion Group (OTCBB:SLGR), Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) , PetroSun, Incorporated (PinkSheets:...

  Tags: California Institute of Technology, cartridge, Cell Genesys Inc., Company, patent, Viaspace Inc.

• Bellwether Report Is Currently Following VLNC, CEGE, IIIN, and CURE

  - 2005-05-02

  The Bellwether Report is the leading online financial newsletter, focusing on small-cap emerging growth opportunities. We strive to introduce investors to truly undervalued opportunities in a time-friendly fashion, allowing for optimal entry points and profitable exit points. Today, we will be tracking the following companies to gauge the short-term...

  Tags: Cell Genesys Inc., FINANCE, MARKETING, Nasdaq Stock Market Inc.

Additional Resources

• Get a Deep Insight into the World Gene Therapy Market

  - 2008-12-16

  NEW YORK -- Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. World Gene Therapy Market http://www.reportlinker.com/p098244/World-Gene-Therapy--Market.html This report analyzes the world market for Gene Therapy in Millions of US$. Annual forecasts are...

• Cell Genesys Announces "Modified Dutch Auction" Tender Offer for up to $80 Million Aggregate Principal Amount of Its Convertible Debt Securities

  - 2008-11-07

  SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that it has commenced a "Modified Dutch Auction" tender offer for a portion of its outstanding 3.125% Convertible Senior Notes due 2011. Under the "Modified Dutch Auction" procedure, Cell Genesys is offering to purchase, for cash, up...

• Cell Genesys Reports Third Quarter 2008 Financial Results

  - 2008-11-06

  Conference Call Scheduled for 4:30 p.m. ET Today SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the third quarter ended September 30, 2008. The net loss for the quarter ended September 30, 2008, was $8.4 million ($0.10 per fully diluted share), compared...

• Cell Genesys to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

  - 2008-11-05

  SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update on Wednesday, November 12, 2008, at 2:25 p.m. ET at the Rodman & Renshaw 10th Annual Healthcare Conference being held in...

• Cell Genesys to Webcast Third Quarter 2008 Conference Call

  - 2008-10-30

  SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's third quarter financial results that will...

• Cell Genesys Announces Receipt of Nasdaq Staff Deficiency Notice Relating to Non-Compliance With a Nasdaq Stock Market Listing Requirement

  - 2008-10-22

  SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE) today announced that it has received a letter from The Nasdaq Stock Market dated October 21, 2008, indicating that the Company had become non-compliant with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Global Market as set...

• BellwetherReport.com Analyst Opinions on EBAY, CEGE, FALC and COST

  - 2008-10-16

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

• Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results

  - 2008-10-16

  Restructuring of Business Operations Implemented Conference Call Scheduled for 8:30 a.m. ET Today SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer. The...

• Beacon Equity Issues Technical Trade Alerts on Market Movers: DNDN, SPSN, SONS, CEGE, IDEV, ARDM

  - 2008-10-07

  DALLAS, Oct. 7 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Dendreon Corp. , Spansion Inc. , Sonus Networks Inc. ,...

• Cell Genesys to Present at the UBS Global Life Sciences Conference

  - 2008-09-15

  SOUTH SAN FRANCISCO, Calif. -- Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the UBS Global Life Sciences Conference in New York City on Monday, September 22, 2008, at 11:30 a.m. ET. ...

• Incorporated: 1988
• CEO: Dr. Stephen A. Sherwin M.D.